ArticleExperimental & molecular medicine2026
Osteoblast-derived osteomodulin restrains osteoclastogenesis via ITGB8/RRM2-mediated reduction of mitochondrial respiration and mitochondrial ATP production.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A circuit linking dentate gyrus and retrosplenial granular cortex regulates fracture healing in male mice.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is driven in part by excessive osteoclast-mediated bone resorption, yet osteoblast-derived extracellular cues that restrain osteoclast bioenergetics remain incompletely defined. Here we identify osteomodulin (OMD), a matrix-associated osteoblast-derived protein that is reduced in the bone tissue and serum of postmenopausal patients with osteoporosis. Inducible global or osteoblast-specific Omd deletion exacerbates bone loss and increases osteoclast activity, whereas osteoclast precursor-specific deletion produces no overt skeletal phenotype. Mechanistically, OMD engages integrin β8 on osteoclast precursors, suppresses RhoA activity and enhances YAP phosphorylation, thereby reducing YAP/TEAD occupancy at the ribonucleotide reductase M2 (RRM2) promoter and repressing Rrm2 transcription. Consistent with RRM2's role in maintaining the dNTP pools required for mitochondrial DNA replication, OMD decreases mtDNA copy number and the abundance of electron transport chain proteins, leading to reduced mitochondrial respiration and ATP production, with only limited glycolytic compensation. Finally, recombinant OMD supplementation or pharmacologic RRM2 inhibition mitigates ovariectomy and lipopolysaccharide-induced bone loss. Together, our findings identify an OMD-integrin β8-RhoA-YAP/TEAD-RRM2 axis that links extracellular matrix signaling to mitochondrial respiration and mitochondrial ATP production during osteoclastogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.